STATICIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Staticin, and when can generic versions of Staticin launch?
Staticin is a drug marketed by Westwood Squibb and is included in one NDA.
The generic ingredient in STATICIN is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staticin
A generic version of STATICIN was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for STATICIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 61 |
Formulation / Manufacturing: | see details |
DailyMed Link: | STATICIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for STATICIN
US Patents and Regulatory Information for STATICIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Westwood Squibb | STATICIN | erythromycin | SOLUTION;TOPICAL | 050526-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |